═══════════════════════════ FOR MID-SIZE PHARMA
═══════════════════════════
ESTABLISHED PIPELINES...
Portfolio Optimization for Strategic Pipeline Management
You're managing 5–15 active programs across multiple therapeutic areas. Unlike Big Pharma, you can't afford to run full development programs on every candidate. Unlike biotech, you can't bet the company on a single asset.
TITAN™ helps mid-size pharmaceutical companies make smarter portfolio allocation decisions, prevent late-stage attrition, and optimize resource deployment across multiple development programs.
Not sure which service tier fits your needs?
[View Service Tiers & Pricing ]
Looking for a different customer segment?
[Biotech Startups] | [Large Pharma] | [Other Organizations]
PORTFOLIO COMPLEXITY
THE MID-SIZE PHARMA DILEMMA
Smart Resource Allocation in a Competitive Landscape
You are in the challenging middle ground of development. Every R&D dollar must be allocated strategically, and every program decision impacts your competitive position.
Positively Impacting Mid-Size Pharma:
The Resource Allocation Challenge:
-
Competing Priorities: 5–15 programs demand resources simultaneously against a limited R&D budget.
-
Limited R&D Budget: Managing multiple programs simultaneously demands earlier decision-making intelligence.
-
The Traditional Problem: By the time you receive comprehensive toxicology data, you've already invested $5M–$15M per program.
-
Strategic Need: Identify "losers" early enough to facilitate expedited de-prioritization and redirect budget to more promising assets.
Competitive & Regulatory Pressures and The Market Reality
Late-stage attrition remains a significant threat, with 30% of Phase II/III failures attributed to safety issues discovered too late. A single failed Phase II program can cost $25M–$75M and 2-3 years of lost opportunity.
THE TITAN™ ADVANTAGE
FROM SEQUENTIAL VALIDATION TO PARALLEL INTELLIGENCE
Transforming Portfolio Management
Move from "validate everything and hope" to "screen intelligently, then validate winners"
The Strategic Solution:
Stage 1: Multi-Program Screening
-
Evaluate candidates and identify programs with unacceptable risk/reward ratios.
-
Compare Safety Profiles: Evaluate backup compounds and different therapeutic areas head-to-head.
-
Early Warning System: Detect problematic toxicity patterns before committing to expensive GLP investment.
Stage 2: Regulatory & BD Excellence
-
Generate preliminary safety packages that exceed FDA expectations and maximize asset valuation for partnership negotiations.
-
Pre-IND Meeting Prep: Generate preliminary safety packages that exceed FDA expectations and build regulatory confidence.
-
Business Development Premium: Command higher licensing valuations by presenting comprehensive safety differentiation.
What TITAN™ Reveals
-
Differentiation Opportunities: Identify superior safety profiles to distinguish your "me-too" compounds from competitors.
-
Mechanistic Understanding: Inform clinical monitoring plans and risk mitigation strategies with predictive biomarkers.
-
Investigator Confidence: Use high-depth characterization to make your Phase I site selection a competitive advantage.
-
Business Development Premium: Advanced preclinical capabilities attract premium buyers and higher licensing valuations.
PORTFOLIO TRANSFORMATION
FROM REACTIVE TO PREDICTIVE
Data-Driven Portfolio Management
The cost of screening 5 programs with TITAN™ ($750K–$1.25M) is less than the typical cost of one failed Phase I study ($10M–$15M).
The Competitive Timeline Advantage:
-
Development Acceleration: Rapidly optimize your portfolio instead of waiting years for sequential results.
-
Resource Optimization and Reallocation: Redirect budget from doomed programs to assets with validated safety profiles. Move capital from "at-risk" programs to assets with validated safety profiles.
-
Value Creation: Comprehensive safety data commands premium pricing and expedites partnership discussions.
-
Market Entry: Faster IND submissions supported by comprehensive preliminary safety narratives.
RECOMMENDED STRATEGY
THE MID-SIZE PHARMA APPROACH
Comprehensive Validation Designed for Strategic Decision-Making
Most Mid-Size Pharma Choose: Comprehensive Tier ($250K per compound)
The Comprehensive Tier provides the multi-modal imaging, full histopathology, and board-certified review necessary to maximize asset valuation for partnership negotiations and internal Go/No-Go decisions, as well as support high-stakes portfolio reviews and partnership due diligence.
-
Multi-Modal Data: SPECT/CT + MRI + Full Histopathology providing maximum dataset depth for maximum understanding and regulatory and BD credibility.
-
Full Histopathology Service: H&E, TUNEL, and board-certified pathologist review.
-
Board-Certified Review: Professional pathologist review and mechanistic toxicity mapping.
-
Regulatory-Ready Analysis: Publication-quality documentation and figures for internal stakeholders and external partners and formal IND submissions.
-
Mechanistic Insights: Spatial-temporal toxicity progression mapping to inform Lead Optimization.
-
Volume Pricing: Strategic discounts available for multi-program pipeline assessments.
Strategic Deployment: Deploy TITAN™ after hit-to-lead optimization but before major lead optimization investments to inform dose optimization and GLP study design.
REPRESENTATIVE ROI
REGULATORY EXCELLENCE MODEL
Theoretical Case Study: Global Pharma (Novel CAR-T Platform)
-
The Challenge: Your company is investing $300M+ in a next-gen CAR-T therapy and needs to differentiate from competitors that failed due to "unexpected" neurotoxicity.
-
The Strategic Outcome:
-
Identified Winners: 2 programs showed significantly superior safety margins compared to competitive benchmarks.
-
Risk Mitigation: 2 programs with "hidden" severe cardiotoxicity were terminated immediately, avoiding $10M+ in failed GLP costs.
-
Value Creation: 1 candidate with a unique safety profile was identified as a prime asset for a high-value out-licensing deal.
-
-
The Financial Impact:
-
Resource Optimization: $45M in downstream development capital redirected to the highest-probability winners.
-
Timeline Acceleration: IND submission for the lead candidate moved forward by 12 months due to data-driven prioritization.
-
Projected ROI: A 2,400% return on the TITAN™ investment based on avoided failure costs and accelerated time-to-market.
-
-
The Financial Impact: $45M redirected to winners, $25M upfront from out-licensing, and a 2,400% ROI on the TITAN™ investment.
THE BOTTOM LINE:
STRATEGIC CAPITAL DEPLOYMENT
TITAN™ transforms your R&D budget from a "sunk cost" into a strategic lever. By investing less than 2% of a typical Phase II budget into early TITAN™ screening, Mid-Size Pharma companies effectively insure their pipeline against late-stage attrition while simultaneously creating a 10x–20x multiplier on asset valuation for potential partners or acquirers.
READY TO OPTIMIZE YOUR PORTFOLIO?
Strategic Intelligence for Smarter Resource Allocation
What You'll Receive:
-
Custom Portfolio Strategy: Program prioritization recommendations based on your pipeline goals.
-
Detailed Investment Proposal: Timeline and deliverables integrated with your development roadmaps.
-
Integration Plan: Tailored strategies for Candidate Prioritization, Pre-IND, and IND submissions.
Questions? Contact Our Scientific Team:
Phone: (414) 465-8654
Email: inquiries@durametrix.com
Our team reviews all inquiries daily. You can expect a response from a technical lead by the next business day.